Related Experiment Videos
Primary CNS lymphoma
1Center for Neuro-Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Seminars in Oncology
|June 22, 1999
Summary
Primary CNS lymphoma (PCNSL) treatment is evolving. While radiation offers initial remission, chemotherapy shows promise for prolonged survival, though optimal strategies require further definition.
Area of Science:
- Neuro-oncology
- Hematology
- Clinical Oncology
Background:
- Primary CNS lymphoma (PCNSL) incidence is rising in immunocompetent and immunocompromised individuals.
- Historically, radiation therapy was standard, achieving remissions but often followed by relapse and short survival (<2 years).
Purpose of the Study:
- To review current management of PCNSL.
- To address key questions regarding optimal chemotherapy regimens and the role of radiation therapy.
- To provide recommendations for future treatment strategies.
Main Methods:
- Literature review of primary CNS lymphoma management.
- Analysis of historical and current treatment outcomes.
- Discussion of unresolved questions in PCNSL therapy.
Main Results:
- Chemotherapy is altering the natural history of PCNSL, with evidence of significantly prolonged survival in certain patient groups.
- Optimal chemotherapy agents, doses, schedules, and routes of administration remain undefined.
- The necessity and timing of radiation therapy in conjunction with chemotherapy are not yet established.
Conclusions:
- Current PCNSL management requires further optimization.
- Further research is needed to define the best chemotherapy regimens and the role of radiation therapy.
- Recommendations are proposed for designing future clinical trials and treatment protocols for PCNSL.